UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 非ヌクレオシド系逆転写酵素阻害剤の薬理学 pharmacology of non nucleoside reverse transcriptase inhibitors
2. HIV抗レトロウイルス療法に関する臨床試験：非ヌクレオシド系逆転写酵素阻害剤 clinical trials of hiv antiretroviral therapy non nucleoside reverse transcriptase inhibitors
3. 未治療HIV感染患者のための抗レトロウイルス療法の選択 selecting antiretroviral regimens for the treatment naive hiv infected patient
4. 妊娠時の抗レトロウイルス剤：非ヌクレオシド系逆転写酵素阻害剤 antiretroviral medications in pregnancy non nucleoside reverse transcriptase inhibitors
5. HIV抗レトロウイルス療法に関する臨床試験：プロテアーゼ阻害剤と非ヌクレオシド系逆転写酵素阻害剤の比較 clinical trials of hiv antiretroviral therapy protease inhibitors versus non nucleoside reverse transcriptase inhibitors

English Journal

Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002-09.

Burchell AN, Bayoumi AM, Rourke SB, Major C, Gardner S, Sandstrom P, Rachlis A, Taylor D, Mazzulli T, Fisher M, Brooks J; on behalf of the OHTN Cohort Study Research Team.SourceOntario HIV Treatment Network, Toronto, Canada.
The Journal of antimicrobial chemotherapy.J Antimicrob Chemother.2012 Nov;67(11):2755-2765. Epub 2012 Jul 24.
OBJECTIVES: To characterize persons undergoing HIV genotypic resistance testing (GRT) while treatment naive and to estimate the prevalence of transmitted HIV drug resistance (TDR) among HIV-positive outpatients in Ontario, Canada.METHODS: We analysed data from a multi-site cohort of persons receivin
PMID 22833637

Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine.

Frasco MA, Mack WJ, Van Den Berg D, Aouizerat BE, Anastos K, Cohen M, De Hovitz J, Golub ET, Greenblatt RM, Liu C, Conti DV, Pearce CL.SourceaDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles bSchool of Nursing cInstitute for Human Genetics, University of California, San Francisco, California dDepartment of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York eDepartment of Medicine, Stroger Hospital and Rush University, Chicago, Illinois fDepartment of Preventive Medicine and Community Health, SUNY Health Sciences Center, Brooklyn, New York gDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland hDepartment of Clinical Pharmacy, Medicine, Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California iDepartment of Medicine, Georgetown University School of Medicine, Washington, District of Columbia, USA.
AIDS (London, England).AIDS.2012 Oct 23;26(16):2097-2106.
OBJECTIVE:: CYP2B6 variation predicts pharmacokinetic characteristics of its substrates. Consideration for underlying genetic structure is critical to protect against spurious associations with the highly polymorphic CYP2B6 gene. DESIGN:: The effect of CYP2B6 variation on response to its substrates,
PMID 22951632

Japanese Journal

Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia

BioScience Trends 10(1), 42-46, 2016
NAID 130005133310

Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors

Biological and Pharmaceutical Bulletin 39(3), 450-454, 2016
NAID 130005132309

Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia

BioScience Trends advpub(0), 2016
NAID 130005129191

Related Pictures

Non-Nucleoside HIV (img thanks to Figure 1. Mechanism of Action of NNRTIs NNRTIs, Delavirdine, Efavirenz, Nevirapine Nat Med 9(7):867-873, 2003. © 2003 This is an open access article distributed reverse-transcriptase inhibitors (NNRTIs Figure 1. NNRTI Mechanism of Action and NNRTIs Mode of action